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Temozolomide is an orally administered alkylating agent which is used in the 
standard of care for glioblastoma, based on a randomized phase 3 study reported by the 
European Organisation for Research and Treatment of Cancer Brain Tumor and 
Radiotherapy Groups and the National Cancer Institute of Canada Clinical Trials Group in 
March 2005. In this multi-institutional study, the median survival of patients receiving 
radiation and temozolomide was significantly improved at 14.6 months compared to 12.1 
months with only radiation. However, such prolonged survival is still not satisfactory. To 
improve the efficacy of temozolomide treatment, combination chemotherapy with other 
agents has also been extensively studied. For instance, a synergistic effect has been 
demonstrated and reported by Balzarotti, M., et al. when temozolomide was used in 
combination with doxorubicin. But the possible mechanisms were not elaborated upon. 
Firstly, my study investigated the mechanisms of the synergistic effect obtained 
using temozolomide in combination with doxorubicin. In vitro, glioma cells were treated 
with varying doses of temoxolomide, doxorubicin, or combination of both. Cytotoxicity assay 
was performed using the method of trypan blue dye-exclusion assay. Synergism between 
temozolomide and doxorubicin against glioma cell lines were evaluated using isobologram 
analysis which is an established method to test the synergism. To assess the intracellular 
retention of doxorubicin in cells treated with doxorubicin with or without temozolomide, flow 
cytometry was utilized to detect mean fluorescence intensity of intracellular doxorubicin 
with an excitation wavelength at 488 nm. The expression levels of P-glycoprotein (P-gp) 
protein in glioma cells after in vitro treatment with temozolomide were evaluated by 
western blot analysis. The adenosine triphosphatase (ATPase) activities of P-gp were 
determined using the luminescent ATP detection kit (Pgp-Glo Assay Systems, Promega, 
Madison, WI) to assess the activity of P-gp with or without temozolomide treatment. The 
present in vitro data demonstrated that temozolomide significantly enhanced sensitivity to 
P-gp substrate in glioma cells, particularly in P-gp-overexpressed 9L/ADR cells which was 
made by continuously exposing the 9L cells to stepwise increasing concentrations of 
doxorubicin. Synergetic effects were observed by combining temozolomide and doxorubicin 
in U87MG, 9L, and 9L/ADR cells. Temozolomide significantly increased the accumulation of 
doxorubicin in these cells. Although temozolomide did not affect the expression of P-gp 
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protein, it inhibited the ATPase activity of P-gp as determined by ATPase assay. These 
results illustrated that temozolomide can reverse doxorubicin resistance by directly 
affecting P-gp transport activity.  
Based on above in vitro findings, efficacy of combinational treatment with 
temozolomide and doxorubicin against 9L brain tumor xenograft model was evaluated in 
order to develop novel effective treatment strategy. Thirty-nine rats that received 9L tumor 
cell implants were randomly divided into four groups: control group (n = 9), temozolomide 
group (n = 10), polyethylene glycol-coated liposomal doxorubicin (PLD; doxorubicin 
hydrochloride liposome injection) group (n = 10), and combination group (n = 10). Seven days 
after tumor implantation, convection-enhanced delivery (CED), a local intratumoral infusion 
method, infused 20 μL of PLD solution (containing 4 μg doxorubicin) was performed in the 
PLD and combination groups. CED infusion of 20 μL of phosphate buffered saline (PBS) was 
performed as a control in the control and temozolomide groups. Temozolomide (350 mg/m2/d) 
at a dose of 90 mL/m2 was given systemically (intraperitoneal administration) daily for 5 
days, starting on day 5 after tumor implantation, in the temozolomide and combination 
groups. Result showed that temozolomide combined with doxorubicin significantly prolonged 
the survival of glioma-bearing rats compared to single agent treatment.  
These findings suggest that combination chemotherapy using temozolomide and 
doxorubicin can be effective against gliomas. 
 
